Array BioPharma Inc (NASDAQ:ARRY) has joined forces with Bristol-Myers Squibb Company (NYSE:BMY) to carry out clinical trials into a potential combination treatment for colorectal cancer.
Array will combine its investigational MEK inhibitor, binimetinib that can halt the growth of tumours. with Bristol-Myers’s immuno-ocology blockbuster Opdivo (nivolumab) and also Opdivo and Yervoy (ipilimumab).
Ron Squarer, Array’s chief executive, said: "Based on emerging data, we believe that studying combinations of targeted therapies, such as binimetinib, with immuno-oncology agents, such as Opdivo and Yervoy, could provide important scientific advances for patients fighting cancer."
The Phase 1/2 study is expected to establish recommended dose regimens for further study and explore the preliminary anti-tumor activity of the combinations. Results from this first study will determine optimal approaches to further clinical development.
Array will organise the study with both companies providing financial support.